

Difficulties of Choosing Proper Endpoints in Anti-Obesity Therapy Assessment

Holownia-Voloskova M-1,2, Czech M-1,3, Franek E-4

1 - Institute of Mother and Child, Warsaw, Poland, 2 - Certara, Cracow, Poland; 3 - Warsaw, University of Technology, Warsaw, Poland, 4 - Central Clinical Hospital of the Ministry of Internal Affairs in Warsaw, Warsaw, Poland

Multifaceted approach, integrating weight, metabolic health, quality of life, and safety profiles, is needed in anti-obesity treatment assessment to provide a complete assessment of therapy efficacy

Background & Objective

To explore the challenges associated with selecting appropriate endpoints in the assessment of anti-obesity therapies, considering the multifactorial nature of obesity and the diverse impacts of treatment modalities.

Methods


A comprehensive review of the literature was conducted, focusing on clinical trials and observational studies evaluating anti-obesity therapies. The review included studies published in peer-reviewed journals between 2000 and 2023. Key endpoints such as weight loss, metabolic health, quality of life, and adverse events were analyzed. Additionally, expert opinions and guidelines from regulatory bodies were examined to understand the rationale behind endpoint selection.

Results

The review identified several challenges in endpoint selection. Weight loss, a commonly used primary endpoint, does not capture the full spectrum of benefits and risks associated with anti-obesity treatments. Metabolic health markers, such as blood glucose and lipid levels, provide crucial insights into the physiological impact of treatments but may not reflect overall health improvements. Quality of life measures are essential for understanding patient-centered outcomes but are often subjective and difficult to standardize. Moreover, the variability in patient responses and the influence of external factors like diet and physical activity complicate endpoint determination. Regulatory requirements often prioritize short-term efficacy endpoints, potentially overlooking long-term health benefits and safety profiles.

Conclusions

Selecting appropriate endpoints for anti-obesity therapy assessment is complex and requires a multifaceted approach. A combination of weight loss, metabolic health indicators, quality of life assessments, and safety profiles should be considered to provide a comprehensive evaluation of treatment efficacy. Future research should focus on developing standardized, holistic endpoints that encompass the broad impact of anti-obesity therapies on patient health and well-being. Collaborative efforts between clinicians, researchers, and regulatory bodies are crucial to establish robust guidelines that reflect the diverse needs of patients undergoing anti-obesity treatment.



References:

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med*. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131.
2. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. *JAMA*. 2024 Jan 2;331(1):38-48. doi: 10.1001/jama.2023.24945. PMID: 38078870; PMCID: PMC10714284.
3. Carlsson LMS, Sjöholm K, Jacobson P, Andersson-Assarsson JC, Svensson PA, Taube M, Carlsson B, Peltonen M. Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study. *N Engl J Med*. 2020 Oct 15;383(16):1535-1543. doi: 10.1056/NEJMoa2002449. PMID: 33053284; PMCID: PMC7580786.
4. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.